Thursday, Can-Fite BioPharma Ltd. (CANF) announced encouraging results from its Phase 2a clinical trial for namodenoson, a drug aimed at treating advanced pancreatic cancer.
In the study, more than 30 percent of the patients who could be evaluated had stable disease, and a few were able to stay on the treatment for quite a while; one patient even went beyond 16 months.
Right now, around 35 percent of the patients are still receiving therapy, suggesting this drug could provide lasting benefits, especially since these patients had already undergone a lot of previous treatments.
The company plans to share more detailed efficacy data, including survival rates, in the months ahead.
CANF is currently trading at $3.43, up $0.44 or 14.72 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.